Search

Objective: The time in therapeutic range (TTR) of international normalized ratio (INR) is essential for the safety and efficacy of warfarin treatment. In this study, we aimed to determine TTR and the factors that affect TTR in patients using warfarin., Methods: Patients taking warfarin for valvular and nonvalvular atrial fibrillation (AF) or prosthetic heart valves who were admitted to our cardiology outpatient clinic were enrolled. TTR was calculated using the linear interpolation method. The patients were analyzed according to warfarin indications and TTR efficiency (TTR ≥60%). Weekly warfarin dose, the duration of warfarin use, the frequency of INR visits per year, and the awareness of patients regarding target INR were noted., Results: The TTR of 248 patients (aged 57.21±12.45 years, 33.1% male) was 55.92±27.84%, and 48.0% patients exhibited efficient TTR. Clinical and demographic characteristics (age, sex, socioeconomic status, and comorbidities) exerted no effect on TTR and TTR efficiency. The frequency of INR visits per year was 10.02±3.80. TTR was related to the frequency of annual INR visits (r=0.131, p=0.039). Only one-third (30.2%) of patients were aware of their target INR. The literacy of the patients and duration of warfarin use exerted a positive effect on awareness (p=0.011 and p=0.024, respectively)., Conclusion: The findings of our study demonstrated that TTR and TTR efficiency were low and not associated with the characteristics of patients or indications. Unfortunately, in patients with valvular AF and prosthetic valves, warfarin is the sole drug that can be used. Thus, awareness and knowledge regarding target INR are essential to overcome poor anticoagulation monitoring with frequent INR visits.

Objective: Prosthetic valve endocarditis (PVE) is associated with increased mortality and morbidity. Information regarding the long-term outcome of PVE is scarce in Turkey. The aim of this study was to evaluate long-term mortality rates of PVE and identify predictors of mortality in these patients., Methods: From January 2008 through August 2013, 44 patients (25 male, 19 female; mean age 49.3±12.1 years) who received a definitive diagnosis of PVE enrolled in the study.Median follow-up period was 23 months. Survival status was assessed for each patient by reviewing charts and making contact by phone. Cox regression analysis was used to evaluate outcome predictors., Results: The mitral valve was the most commonly affected valve and Staphylococcus aureus the most prevalent microorganism. Fourteen patients (32%) underwent surgery, 7 of whom underwent early surgery. Overall mortality and in-hospital mortality rates were 39% (n=17) and 25% (n=11), respectively. In multivariate analysis, NYHA classification >2 (hazard ratio [HR] 3.7; 95% confidence interval [CI], 1.16-11.8; p=0.03), early-onset PVE (HR 4.23; 95% CI, 1.1-16.42; p=0.04), vegetation size ≥10 mm (HR 3.94; 95% CI, 1.1-14.75; p=0.04), and heart failure (HR 4.18; 95% CI, 1.36-12.8; p=0.01) were found to be independent predictors of mortality., Conclusion: Our findings suggest that PVE is associated with increased long-term mortality rates. Poor functional status, early-onset PVE, heart failure, and vegetation size are independent predictors of survival in patients with PVE.

Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients., Study Design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization)., Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016., Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).

Objectives: To detect the prevalence of alternative herbal medicine and nutritional complementary product intake in patients admitted to outpatient cardiology clinics and to determine demographic characteristics, comorbidities and medical properties of those patients., Study Design: Patients admitted to outpatient cardiology clinics between June 2011 and March 2012 were given questionnaires involving age, gender, education, occupation, chronic illness, medication, herbs, nutritional complementary products, the index purpose and motivation for using herbs and nutritional complementary products. The data of those questionnaires were analyzed., Results: A total of 454 questionnaires were collected. The mean age was 49±13 and 48% of the participants were female. Of those patients, 12% had diabetes, 34% had hypertension, 26% had coronary artery disease, 7% had heart failure, 58% had chronic illness, 49% had cardiovascular disease, and 57% had history of drug intake. Including vitamins and minerals, there were 75 (16%) patients taking alternative and complementary medicine. When vitamins and minerals were excluded, 56 (12%) patients were using at least one product, while 24 (5%) patients were using more than one. Garlic (n=33), flaxseed (n=13), ginger (n=12), omega 3 (n=12), and turmeric (n=11) were the most popular products. Of those 56 patients, 32% were using alternative medicine for hypertension and 23% for hyperlipidemia treatment, while 20% were using those products to be healthier in general. Alternative medicine was more prominent in females (p=0.04), and older patients (p=0.004). Education level, drug intake, and the presence of chronic illnesses, hypertension and cardiovascular disease were significantly higher in those patients., Conclusion: Alternative and complementary products were common in patients admitted to outpatient cardiology clinics. Female gender, advanced age, higher education level, drug intake, and having a chronic illness were predisposing factors.